Grifols SA (GRFS)
6.28
-0.26
(-3.98%)
USD |
NASDAQ |
Apr 19, 16:00
6.29
+0.01
(+0.16%)
After-Hours: 20:00
Grifols Enterprise Value: 16.87B for April 19, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 19, 2024 | 16.87B |
| April 18, 2024 | 17.05B |
| April 17, 2024 | 17.07B |
| April 16, 2024 | 17.21B |
| April 15, 2024 | 17.05B |
| April 12, 2024 | 17.06B |
| April 11, 2024 | 17.12B |
| April 10, 2024 | 17.34B |
| April 09, 2024 | 17.48B |
| April 08, 2024 | 17.55B |
| April 05, 2024 | 17.42B |
| April 04, 2024 | 17.26B |
| April 03, 2024 | 17.28B |
| April 02, 2024 | 17.21B |
| April 01, 2024 | 17.14B |
| March 28, 2024 | 17.14B |
| March 27, 2024 | 17.12B |
| March 26, 2024 | 17.00B |
| March 25, 2024 | 16.92B |
| March 22, 2024 | 16.83B |
| March 21, 2024 | 17.21B |
| March 20, 2024 | 16.88B |
| March 19, 2024 | 16.72B |
| March 18, 2024 | 16.71B |
| March 15, 2024 | 16.77B |
| Date | Value |
|---|---|
| March 14, 2024 | 16.52B |
| March 13, 2024 | 16.91B |
| March 12, 2024 | 16.88B |
| March 11, 2024 | 17.20B |
| March 08, 2024 | 17.36B |
| March 07, 2024 | 16.41B |
| March 06, 2024 | 16.32B |
| March 05, 2024 | 16.79B |
| March 04, 2024 | 17.11B |
| March 01, 2024 | 17.40B |
| February 29, 2024 | 17.70B |
| February 28, 2024 | 18.95B |
| February 27, 2024 | 18.92B |
| February 26, 2024 | 18.91B |
| February 23, 2024 | 18.80B |
| February 22, 2024 | 18.51B |
| February 21, 2024 | 18.55B |
| February 20, 2024 | 18.40B |
| February 16, 2024 | 18.36B |
| February 15, 2024 | 18.46B |
| February 14, 2024 | 18.49B |
| February 13, 2024 | 18.30B |
| February 12, 2024 | 18.31B |
| February 09, 2024 | 18.23B |
| February 08, 2024 | 18.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
12.09B
Minimum
May 31 2019
24.17B
Maximum
Feb 21 2020
18.89B
Average
19.06B
Median
Aug 27 2020
Enterprise Value Benchmarks
| DBV Technologies SA | -9.363M |
| Adaptimmune Therapeutics PLC | 94.14M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -13.96M |
| Autolus Therapeutics PLC | 955.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 60.30M |
| Revenue (Quarterly) | 1.906B |
| Total Expenses (Quarterly) | 1.812B |
| EPS Diluted (Quarterly) | 0.0888 |
| Gross Profit Margin (Quarterly) | 38.98% |
| Profit Margin (Quarterly) | 3.16% |
| Earnings Yield | 4.95% |
| Operating Earnings Yield | 18.85% |
| Normalized Earnings Yield | 3.395 |